PT2950648T - Soluções oftálmicas aquosas de fentolamina e usos médicos - Google Patents

Soluções oftálmicas aquosas de fentolamina e usos médicos

Info

Publication number
PT2950648T
PT2950648T PT147462089T PT14746208T PT2950648T PT 2950648 T PT2950648 T PT 2950648T PT 147462089 T PT147462089 T PT 147462089T PT 14746208 T PT14746208 T PT 14746208T PT 2950648 T PT2950648 T PT 2950648T
Authority
PT
Portugal
Prior art keywords
phentolamine
medical uses
aqueous ophthalmic
ophthalmic solutions
solutions
Prior art date
Application number
PT147462089T
Other languages
English (en)
Original Assignee
Ocuphire Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocuphire Pharma Inc filed Critical Ocuphire Pharma Inc
Publication of PT2950648T publication Critical patent/PT2950648T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT147462089T 2013-02-01 2014-01-31 Soluções oftálmicas aquosas de fentolamina e usos médicos PT2950648T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361759530P 2013-02-01 2013-02-01

Publications (1)

Publication Number Publication Date
PT2950648T true PT2950648T (pt) 2020-01-06

Family

ID=51259735

Family Applications (1)

Application Number Title Priority Date Filing Date
PT147462089T PT2950648T (pt) 2013-02-01 2014-01-31 Soluções oftálmicas aquosas de fentolamina e usos médicos

Country Status (9)

Country Link
US (6) US9795560B2 (pt)
EP (1) EP2950648B1 (pt)
JP (1) JP6335927B2 (pt)
AU (2) AU2014212274A1 (pt)
CA (1) CA2899339C (pt)
DK (1) DK2950648T3 (pt)
ES (1) ES2762153T3 (pt)
PT (1) PT2950648T (pt)
WO (1) WO2014121027A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9089560B2 (en) 2013-02-01 2015-07-28 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
CA2899339C (en) 2013-02-01 2021-07-06 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
KR102478553B1 (ko) * 2018-02-28 2022-12-16 한림제약(주) 벤조피란 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 용액 형태의 점안제
CA3074618C (en) 2018-04-24 2022-08-02 Allergan, Inc. Presbyopia treatments
JP2022505950A (ja) * 2018-10-26 2022-01-14 オキュフィア・ファーマ・インコーポレイテッド 老眼、散瞳、および他の眼障害の治療のための方法および組成物
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4508715A (en) 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
US4443441A (en) 1981-08-07 1984-04-17 Galin Miles A Fixation of intraocular lenses
US4629456A (en) 1981-09-18 1986-12-16 Edwards David L Target ring for an eye dropper bottle
US4515295A (en) 1983-09-06 1985-05-07 St. Luke's Hospital Eye dropper with light source
US4659714A (en) 1984-03-27 1987-04-21 Dentsply, Ltd. Anesthetic methods for mammals
US4906613A (en) 1985-11-05 1990-03-06 Schering Corporation Antiglaucoma compositions and methods
IE60588B1 (en) 1986-07-30 1994-07-27 Sumitomo Pharma Carbapenem compound in crystalline form, and its production and use
US5032392A (en) * 1986-09-04 1991-07-16 Vision Pharmaceuticals Aqueous ophthalmic solutions for the treatment of dryness and/or irritation of human or animal eyes
US4938970A (en) 1987-02-06 1990-07-03 Hustead Robert E Painless electrolyte solutions
US4834727A (en) 1987-12-08 1989-05-30 Cope Samuel M Eye dropper bottle attachment for post-surgical and general use
US5261903A (en) 1988-04-11 1993-11-16 M.D. Inc. Composite anesthetic article and method of use
US5149320A (en) 1988-04-11 1992-09-22 Dhaliwal Avtar S Composite anesthetic article and method of use
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
FR2647675B1 (fr) 1989-06-05 1994-05-20 Sanofi Utilisation d'un derive de la statine dans le traitement des affections oculaires
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5059188A (en) 1990-03-28 1991-10-22 Goddard Larry C Eye dropper attachment
US5192527A (en) 1991-07-01 1993-03-09 Abrahmsohn Glenn M Method of reversing local anesthesia and reagent system therefor
US5288759A (en) 1992-08-27 1994-02-22 Alcon Laboratories, Inc. Use of certain sulfamoyl-substituted phenethylamine derivatives to reverse drug-induced mydriasis
US5514118A (en) 1992-12-23 1996-05-07 Kummer; Frederick J. Measured dose eye dropper
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
US5494937A (en) * 1994-07-22 1996-02-27 Alcon Laboratories, Inc. Saline solution for treating contact lenses
CA2201134A1 (en) 1994-10-10 1996-04-18 Alfred Sallmann Ophthalmic and aural compositions containing diclofenac potassium
US5792767A (en) 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5584823A (en) 1995-07-20 1996-12-17 Ontario Incorporated Illuminated eye dropper device
US6106866A (en) 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
US5627611A (en) 1995-12-29 1997-05-06 Scheiner; Stanley A. Artificial tears
ZA97452B (en) 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
US6043224A (en) 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
KR100195348B1 (ko) 1996-10-31 1999-06-15 장용택 안정한 프로스타글란딘 e1-함유 주사제 조성물
US5891882A (en) 1996-12-06 1999-04-06 Abbott Laboratories Benzopyranopyrrole and benzopyranopyridine α-1 adenergic compounds
US6001845A (en) 1998-06-19 1999-12-14 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US5885550A (en) 1998-07-02 1999-03-23 Vallier; Deandra K. Ophthalmic whitening solution
US6730065B1 (en) 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6420407B1 (en) 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
US20020082288A1 (en) 1999-09-16 2002-06-27 Gerald Horn Ophthalmic formulations comprising an imidazoline
AU7581000A (en) 1999-09-16 2001-04-17 Gerald D. Horn A method for optimizing pupil size using alpha antagonist
US6730691B1 (en) 2000-02-10 2004-05-04 Miles A. Galin Uses of alpha adrenergic blocking agents
AU5984801A (en) 2000-05-12 2001-11-20 Novalar Pharmaceuticals Inc Local anesthetic methods and kits
US6623765B1 (en) 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
US6515006B2 (en) 2000-11-08 2003-02-04 Hmt Pharma, Inc. Ophthalmic formulation which modulates dilation
US20030236306A1 (en) * 2002-06-20 2003-12-25 Chen Andrew X. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US7229630B2 (en) 2002-06-20 2007-06-12 Novalar Pharmaceuticals, Inc. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
BR0311965A (pt) * 2002-06-20 2005-03-29 Novalar Pharmaceutical Inc Formulações estabilizadas de antagonistas de receptores alfa adrenérgicos e os seus usos
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
JP2007518804A (ja) * 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
WO2006083841A2 (en) 2005-02-01 2006-08-10 Allergan, Inc. Therapeutic esters
US20060257388A1 (en) 2005-05-13 2006-11-16 Julius Knowles Drug delivery systems for stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
WO2007008666A2 (en) 2005-07-08 2007-01-18 Ocularis Pharma, Inc. Compositions and methods for improving vision using adherent thin films
US7629331B2 (en) * 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20090131303A1 (en) * 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
US20090220618A1 (en) * 2008-02-29 2009-09-03 Erning Xia Pharmaceutical formulations comprising polyanionic materials and source of hydrogen peroxide
EP2420223B1 (en) 2008-03-17 2017-07-19 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
EP2320911B1 (en) 2008-08-01 2014-10-08 Eye Therapies LLC Vasoconstriction compositions and methods of use
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
US20130143938A1 (en) 2009-07-27 2013-06-06 Eye Therapies Llc Compositions and Methods for the Treatment of Migraine
US20110178147A1 (en) 2009-10-20 2011-07-21 Allergan, Inc. Compositions and methods for controlling pupil dilation
KR20120098720A (ko) 2009-10-21 2012-09-05 알러간, 인코포레이티드 알파 아드레날린 수용체 변형제
EP3181121B1 (en) 2010-12-03 2020-10-28 EPI Health, LLC Pharmaceutical cream compositions comprising oxymetazoline to treat rosacea
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US20130172357A1 (en) 2011-02-03 2013-07-04 Eye Therapies Llc Compositions and Methods for Treatment of Glaucoma
KR102058756B1 (ko) 2011-02-15 2020-01-22 어클라리스 쎄라퓨틱스, 인코포레이티드 주사비 징후들의 치료용 옥시메타졸린의 약학 크림 조성물들
CA2829040A1 (en) 2011-03-03 2012-09-07 Allergan, Inc. Non-aqueous silicone-based ophthalmic formulations
WO2012149381A1 (en) 2011-04-28 2012-11-01 Alpha Synergy Development, Inc. Compositions and methods for improving night vision
US20130029919A1 (en) * 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
WO2013115844A1 (en) 2012-02-02 2013-08-08 Alpha Synergy Development, Inc. Compositions and methods for treatment of glaucoma
CA2865593A1 (en) 2012-02-27 2013-09-06 Eye Therapies Llc Compositions and methods for the treatment of migraine
US9089560B2 (en) 2013-02-01 2015-07-28 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
CA2899339C (en) 2013-02-01 2021-07-06 Ocularis Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
US8597629B1 (en) 2013-06-21 2013-12-03 Premium Ocular Solutions LLC. Artificial tear compositions comprising a combination of nonionic surfactants

Also Published As

Publication number Publication date
US20140221445A1 (en) 2014-08-07
JP2016506966A (ja) 2016-03-07
US10772829B2 (en) 2020-09-15
WO2014121027A1 (en) 2014-08-07
US20190254963A1 (en) 2019-08-22
CA2899339C (en) 2021-07-06
EP2950648A1 (en) 2015-12-09
US9795560B2 (en) 2017-10-24
EP2950648B1 (en) 2019-09-18
US20240285519A1 (en) 2024-08-29
CA2899339A1 (en) 2014-08-07
US11090261B2 (en) 2021-08-17
US20190358152A1 (en) 2019-11-28
AU2018200566B9 (en) 2019-06-20
ES2762153T3 (es) 2020-05-22
DK2950648T3 (da) 2019-12-02
AU2014212274A1 (en) 2015-08-13
AU2018200566A1 (en) 2018-02-15
US20220175668A1 (en) 2022-06-09
US20180221274A1 (en) 2018-08-09
EP2950648A4 (en) 2016-07-20
AU2018200566B2 (en) 2019-06-13
JP6335927B2 (ja) 2018-05-30
US10278918B2 (en) 2019-05-07
US11844858B2 (en) 2023-12-19

Similar Documents

Publication Publication Date Title
IL241026B (en) A head device for treating and evaluating medical conditions
IL242825B (en) Systems and methods for diagnosis of depression and other medical conditions
EP3708210B8 (en) Patient interface and aspects thereof
EP3048951A4 (en) PRESSURE-SENSITIVE SURGERY VITRECTOMY SYSTEMS AND METHOD
EP2968397A4 (en) DIAGNOSIS AND TREATMENT OF FIBROSIS
EP2925244A4 (en) Medical device and method of use
EP2967413A4 (en) SYSTEMS AND METHODS FOR MULTISPECTRAL BLOOD ANALYSIS
GB201515688D0 (en) Nasal cannula assemblies and related parts
EP3071161A4 (en) Corneal vitrification, methods and devices to produce corneal vitrification and methods of use thereof
EP2961350A4 (en) NASAL IMPLANTS AND SYSTEMS AND METHODS OF USE
HK1223872A1 (zh) 可控制的醫療設備、系統及使用方法
EP3006738A4 (en) Rapid-discharge-valve structural body and diaphragm pump
EP3067021A4 (en) Medical cast and skin protector
HK1215147A1 (zh) 眼部護理裝置及方法
HK1224020A1 (zh) 延長釋放藥物傳遞的隱形眼鏡及其製造方法
AP2015008835A0 (en) Biocidal systems and methods of use
PT2950648T (pt) Soluções oftálmicas aquosas de fentolamina e usos médicos
EP2965761A4 (en) MELOXICAM EYE DROPS AND MANUFACTURING METHOD AND USE THEREOF
IL241073A0 (en) Thermally stable ligase with smooth ends and methods of use
HK1213209A1 (zh) 用於醫療裝置的主體部分和隔膜材料
HK1211458A1 (en) Disposable body warmer
EP3065674A4 (en) Monolithic medical devices and methods of use
SG10201403043XA (en) Medical face masks
EP3013425A4 (en) Treatment and diagnosis of ocular disease
EP2981556A4 (en) HYALURONIC ACID BIOPOLYMERS ETHYLSULFONATED AND METHODS OF USE